Magenta Therapeutics, Inc. Contracts & Agreements

Separation Agreement, dated September 11, 2023, by and between Magenta Therapeutics, Inc. and Stephen Mahoney (Filed With SEC on November 9, 2023)

Form of Pre-Funded Warrant of the Company (Filed With SEC on September 12, 2023)

Registration Rights Agreement, dated September 11, 2023, by and among the Company, OpCo and certain parties thereto (Filed With SEC on September 12, 2023)

Contingent Value Rights Agreement, dated September 11, 2023, by and between the Company and the Rights Agent (Filed With SEC on September 12, 2023)

Form of Indemnification Agreements for Directors of the Company (Filed With SEC on September 12, 2023)

Form of Indemnification Agreements for Officers of the Company (Filed With SEC on September 12, 2023)

Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (Filed With SEC on September 12, 2023)

Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Marino Garcia (Filed With SEC on September 12, 2023)

Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Ryan Savitz (Filed With SEC on September 12, 2023)

Amendment to Offer Letter, dated September 11, 2023, by and between OpCo and Edward Carr (Filed With SEC on September 12, 2023)

Sublease Termination and Release Agreement by and between the Registrant and Novartis Institutes for Biomedical Research, Inc., dated as of March 31, 2023 (Filed With SEC on May 15, 2023)

Agreement and Plan of Merger, dated as of May 2, 2023, by and among Magenta Therapeutics, Inc., Dio Merger Sub, Inc. and Dianthus Therapeutics, Inc (Filed With SEC on May 3, 2023)

Amendment No. 1 to Stockholder Rights Agreement, dated as of May 2, 2023, by and between Magenta Therapeutics, Inc. and Computershare Trust Company, N.A., as Rights Agent (Filed With SEC on May 3, 2023)

Form of Dianthus Support Agreement (Filed With SEC on May 3, 2023)

Form of Magenta Support Agreement (Filed With SEC on May 3, 2023)

Form of Lock-Up Agreement (Filed With SEC on May 3, 2023)

Form of Contingent Value Rights Agreement (Filed With SEC on May 3, 2023)

Amendment No. 3, effective as of August 1, 2022, to the Exclusive Research, Development Option and License Agreement by and between the Registrant and Heidelberg Pharma Research... (Filed With SEC on November 3, 2022)

Amended and Restated Employment Agreement by and between the Registrant and Thomas Beetham, effective May 2, 2022 (Filed With SEC on May 2, 2022)

Amended and Restated Employment Agreement by and between the Registrant and David Nichols, effective May 2, 2022 (Filed With SEC on May 2, 2022)

Master Services Agreement, dated as of May 22, 2019, by and between the Registrant and Heidelberg Pharma Research GmbH (Filed With SEC on March 8, 2022)

Amended and Restated Employment Agreement by and between the Registrant and Jason Gardner, effective March 3, 2022 (Filed With SEC on March 8, 2022)

Amended and Restated Employment Agreement by and between the Registrant and Stephen Mahoney, effective March 3, 2022 (Filed With SEC on March 8, 2022)

Securities Purchase Agreement, dated as of May 12, 2021, among Magenta Therapeutics, Inc. and each purchaser party thereto (Filed With SEC on May 12, 2021)

Employment Agreement by and between the Registrant and Stephen F. Mahoney, effective November 9, 2020 (Filed With SEC on May 6, 2021)

Amendment #2 to Project Rider #1, effective as of November 13, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a... (Filed With SEC on March 3, 2021)

Amendment #3 to Project Rider #1, effective as of December 16, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a... (Filed With SEC on March 3, 2021)

Amendment #1 to Collaboration Agreement, effective as of December 31, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program... (Filed With SEC on March 3, 2021)

Second Amendment to Sublease Agreement, dated as of August 19, 2020, by and between the Registrant and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on March 3, 2021)

First Amendment to Employment Agreement, executed as of October 14, 2020, by and between the Registrant and John C. Davis, Jr., M.D (Filed With SEC on November 5, 2020)

Underwriting Agreement, dated as of June 24, 2020, by and among Magenta Therapeutics, Inc. and Goldman Sachs & Co. LLC and Cowen and Company, LLC, as representatives of the... (Filed With SEC on June 30, 2020)

Description of Securities of the Registrant (Filed With SEC on March 3, 2020)

Amendment #1 to Project Rider #3, effective as of August 26, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be... (Filed With SEC on November 13, 2019)

Amendment, effective as of July 4, 2019, pursuant to the Exclusive Research, Development Option and License Agreement by and between the Registrant and Heidelberg Pharma Research... (Filed With SEC on November 13, 2019)

2019 Employee Stock Purchase Plan (Filed With SEC on June 11, 2019)

Form of Underwriting Agreement (Filed With SEC on April 29, 2019)

Letter Agreement, effective as of February 28, 2019, by and between the Registrant and Heidelberg Pharma Research GmbH relating to the Exclusive Research, Development Option and... (Filed With SEC on April 29, 2019)

First Amendment to Sublease by and between Novartis Institutes for BioMedical Research, Inc. and the Registrant, dated as of December 13, 2018 (Filed With SEC on April 29, 2019)

Project Rider #2, effective as of June 26, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10, 2017 (Filed With SEC on March 19, 2019)

Project Rider #3, effective as of September 6, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as of November 10,... (Filed With SEC on March 19, 2019)

Amendment #1 to Project Rider #1, effective as of December 6, 2018, pursuant to the Collaboration Agreement by and between the Registrant and Be The Match BioTherapies, dated as... (Filed With SEC on March 19, 2019)

Agreement, dated as of May 31, 2018, by and between the Registrant and The Richmond Group, Inc (Filed With SEC on November 8, 2018)

Master Development and Manufacturing Agreement by and between Bachem Americas, Inc. and the Registrant, dated as of February 13, 2018 (Filed With SEC on June 18, 2018)

Specimen Common Stock Certificate (Filed With SEC on June 8, 2018)

2018 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on June 8, 2018)

First Amendment to Sublease Agreement, dated as of May 30, 2018, by and between the Registrant and Surface Oncology, Inc (Filed With SEC on June 8, 2018)

Form of Underwriting Agreement (Filed With SEC on May 24, 2018)

Second Amended and Restated Investors Rights Agreement by and among the Registrant and certain of its stockholders dated April 2, 2018 (Filed With SEC on May 24, 2018)

2016 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder (Filed With SEC on May 24, 2018)

Senior Executive Cash Incentive Bonus Plan (Filed With SEC on May 24, 2018)

Form of Employment Agreement (Filed With SEC on May 24, 2018)

Form of Indemnification Agreement (Filed With SEC on May 24, 2018)

License Agreement by and between President and Fellows of Harvard College and the Registrant, dated as of November 2, 2016 (Filed With SEC on May 24, 2018)

License Agreement by and between Novartis International Pharmaceutical Ltd. and the Registrant, dated as of April 3, 2017 (Filed With SEC on May 24, 2018)

Collaboration Agreement by and between Be The Match BioTherapies and the Registrant, dated as of November 10, 2017 (Filed With SEC on May 24, 2018)

Clinical Trial Agreement by and between Regents of the University of Minnesota and the Registrant, dated as of January 22, 2018 (Filed With SEC on May 24, 2018)

Master Development and Manufacturing Agreement by and between Bachem Americas, Inc. and the Registrant, dated as of February 13, 2018 (Filed With SEC on May 24, 2018)

Exclusive Research, Development Option and License Agreement by and between Heidelberg Pharma Research GmbH and the Registrant, dated as of March 1, 2018 (Filed With SEC on May 24, 2018)